Avoid recurrent microbial contamination using trending of historical data. El Azab Walid Technical Service Manager STERIS
|
|
- Olivia Skinner
- 6 years ago
- Views:
Transcription
1 Avoid recurrent microbial contamination using trending of historical data El Azab Walid Technical Service Manager STERIS
2 Agenda Factors influencing the cleaning and disinfection performance Recurring microbial contamination observed on the field case studies Good practices for microbial contamination control Conclusion
3 Regulation Requirements: Cross-contamination Control Management for sterile NON EXHAUSTIVE LIST Contamination Sources : I. Biological Cleaning EU GMP: Annex 15 Chapter 3 and 5 EMA Health based US GMP CFR ISPE Risk MaPP PDA TR 29 and 49 PICS/S 006 II. Microorganism Endotoxin Chemical Crosscontamination control Product residue Cleaner residue Other residue Disinfection EU Annex 1 US FDA aseptic guidance and CFR PICS/S 009 JP Guidance for sterile manufacturing Who TRS961 Annex 6
4 Regulation Requirements: Cross-contamination Control Management for non sterile NON EXHAUSTIVE LIST Contamination Sources : I. Biological Cleaning EU GMP: Annex 15 Chapter 3 and 5 EMA Health based Eur. Ph. (5.1.4) US GMP CFR ISPE Risk MaPP PDA TR 29 USP <1111> & USP <1112> PICS/S 006 II. Microorganism Chemical Crosscontamination control Product residue Cleaner residue Other residue Disinfection Chapter 3 and 5 CFR PICS/S 009 WHO TRS961
5 Factors influencing microbial contamination
6 Parameters Affecting Cleaning and Disinfection Performance Equipment design Design is one of the key aspect for effective cleaning and disinfection. 100% recovery should always be reached. Equipment design TACT Time, action, concentration and temperature are considered critical process parameter for effective cleaning Numbers Disinfectant is more effective against low number of microorganism than high number Expiry time TACT Type and resistance Sporicidal agent kills spore and vegetative microorganism. However, non oxidizing disinfectant kill vegetative microorganisms and could kill some spore microorganisms Residue ph & Temperature Numbers Water Hard water could reduce efficacy of many disinfectants Chemistry Type and resistance microorganism Chemistry Residue The choice of the chemistry should depend on the residue nature and aspect Residue should not interfere with the disinfectant efficacy. Rinse strategy should be put in place periodically. Water ph & temperature ph could influence the ionic biding of disinfectant, while temperature could affect the log kill over time (Q10). Expiry time Stability of the component ready to use or diluted need to be assessed. It can flexibility based on the shelf life
7 Agenda Factors influencing the cleaning and disinfection performance Recurring microbial contamination observed on the field case studies Good practices for microbial contamination control Conclusion
8 Case study #1: Recurrent microbial contamination of non sterile batches Recurrent deviation CAPA : CIP design dead leg removal Recurrent deviation CAPA : Increase rinsing step using PW for contact product Increase water system sanitization (from every 4 month 80 C for 30 min -> every 2 month 80 C for 30 min) Increase gloves sanitization (IPA) increase the cleaning/disinfection cleanroom frequency (from weekly to daily)
9 Case study #1: Recurrent microbial contamination of non sterile batches Equipment a. CIP system design: 1. dead leg 2. hoses connection and management b. Water system (PW) maintenance: 1. presence of rouge confirmed 2. recurrent microbial contamination Method f. Room cleaning and disinfection SOP: 1. disinfectant X efficacy vs EM data 2. absence of sporicidal vs EM data c. Water system (PW) sanitization: 1. temperature, time and frequency 2. periodic chemical sanitization d. Process equipment cleaning: 1. water / equipment microbial status 2. cleaner demonstrated not capable to to remove not remove product residueand remove microbial burden Environment Material e. Equipment/Material flows and control : 1. presence of cartons in the rooms 2. equipment flow were not adequate
10 Case Study #2: Non conform microbial level in final product QC testing Recurrent deviation : Root cause unidentified Specification change Action put in place : Increase the concentration: Double for the disinfectant X NaOCl from 1% to 2% Increase the contact time: From 15 min to 45 min 2015
11 Case Study #2: Non conform microbial level in final product QC testing Equipment b. Washing machine deisgn : 1. presence of rouge confirmed 2. recurrent microbial contamination a. Equipment design: 1. presence of rouge (high level) 2. high rugosity of the surfaces crevices & interstice Method d. Room cleaning and disinfection SOP: 1. Inadequate understanding of the disinfectant efficacy vs micro identified c. Process equipment cleaning: 1. Cleaner was inefficient the against microorganism found 2. cleaning cycle was inadequate to ensure effective cleaning visual check not achieved 3. Disinfection program for direct contact area with the product was inadequate Environment Material e. Personnel flow was inadequate f. Material status and maintenance was not enough for effective microbial contamination control
12 Case Study #3: Trend for microbial contamination deviation is increasing every year 45 Number of microbial contamination deviation
13 Case Study #3: Trend for microbial contamination deviation is increasing every year EM data from Non conform EM position from Air Contact plate contact product non contact product floor
14 Case study #3: Trend for microbial contamination deviation is increasing every year Equipment a. CIP system design: 1. dead leg 2. manual cleaning defective Method Environment Material b. Process equipment cleaning: 1. cleaner not capable to remove product residue 2. Manual cleaning leading to microbial contamination c. Cleaning of the equipment : 1. cleaning and disinfection method was ineffective (Spaghetti chart) 2. miss-used of the detergent vs efficacy 3. Disinfectant were not qualify for their use 4. cleaning simultaneously non contact and contact product using the same procedure d. Microbial specification is the same e. Non respect of the material flow and the number of equipment authorized in the area per validation protocol
15 Case study #3: Trend for microbial contamination deviation is increasing every year Short term corrective/preventive actions Actions list A C B D Material Man Method Equipment define adequate material flows clean/unclean increase awareness of microbial contamination factors. review the cleaning and disinfection procedure using a hard surface disinfectant and sporicide review the manual cleaning operation and the cleaning steps riboflavin test for automated equipment with spray ball E F Environment Measure
16 Case study #3: Trend for microbial contamination deviation is increasing every year Long term corrective/preventive actions Actions list A C B D E Material Man Method Equipment Environment reduce the number of detergent and disinfectant. qualify the disinfectant define adequate material flows clean/unclean update the cleaning validation SOP/protocol qualification and re-training review the cleaning and disinfection procedure based on the disinfectant qualification result knowledge transfer task force review the manual cleaning operation riboflavin test and technical upgrade automatic cleaning increase automation by using mobile skid reduce EM testing from intensive to normal F Measure
17 Case study #4: Recurrent Microbial Contamination of WFI Systems Position of the non-conformity Results per point of use (2 nd phase I PQ) Samples at start or return loop were conform
18 Case study #4: Recurrent Microbial Contamination of WFI Systems Source: see the source page
19 Case study #4: Recurrent Microbial Contamination of WFI Systems Source: see the source page
20 Case study #4: Recurrent Microbial Contamination of WFI Systems Short and long term corrective/preventive actions Actions list A C B D Material Man Method Equipment purchase more material and develop visual lean tools for material management update the SOP/protocol qualification and re-training design sampling instruction methods and check list knowledge transfer task force qualification and requalification requirement Purchase new valves E F Environment Measure
21 Case study #4: Recurrent Microbial Contamination of WFI Systems
22 Case Study #5: Non conform microbial level of tank vessel after cleaning hold time testing Description: Cleaning Revalidation: cleaning PW and rinse PW Recurrent contamination by gram - microorganism : P. aeruginosa and P. picketti Several final product with microbial results under USP <1111> specifications and the P. aeruginosa and R. picketti never identified Remedial action Root cause not found: Sanitization of the water system Water results were always conform Microbial analysis of the equipment after each cleaning Remove the clean hold time Identification of each CFU even under specification because consider as objectionable microorganism! After cleaning a 3 log reduction were achieved Cross functional investigation team / Fish bone and microbial screening risk assessment: Root cause: Equipment intra-design inducing water to stagnate Disinfection process was absent vs the equipment design Disassemble the equipment at the end of the week but not during routine testing Actions put in place but removed: Implement a disinfectant peroxide hydrogen impact on the product coloration
23 Case Study #6: The disinfectant is not working Description: Grade D and grade C: after application of the phenolic disinfectant the microbial testing is higher than prior application In vitro coupon testing were conform to the specifications with 5 minutes contact time micro identified: Staphylococcus epidermidis, Staphylococcus aureus and other human microorganism. Remedial action Root cause not found: Replace the current disinfectant with another phenolic disinfectant Review the procedure and increase the contact time
24 Case Study #6: The disinfectant is not working
25 Agenda Factors influencing the cleaning and disinfection performance Recurring microbial contamination observed on the field case studies Good practices for microbial contamination control Conclusion
26 Approach for Cleaning and Disinfection Process and non- Process Equipment A Soils and microbial Residue type and level A INDUSTRY PRACTICE Microbial residue: Is the cleaner agent used efficient B Surface And Equipment Design B Material substrate, area classification, design C C Cleaning and disinfection program based on risk based assessment PDA TR13: it is recommended to periodically review challenge testing of the selected sanitizers, disinfectants and sporicide if representative new isolate are routinely recovered in the EM program Source: Image from McDonnell, Antisepsis, Disinfection, and Sterilization: Types, Action, and Resistance 2007, ASM Press
27 Cleaning and disinfection strategy must be based on the sampling risk level Step 1: Risk Factor determination EXAMPLE Step 2: Risk Factor determination Duration Proximity # People Risk Class Step 3: Design the cleaning and disinfection SOP
28 Microbial contamination reflect inadequate motion work Assess (Risk-based) and control factor(s) that influence microbial contamination during your manufacturing process Develop robust process, cleaning and disinfection, preventive maintenance program Trend and control your data for preventive action and avoid deviation If a deviation the solution is on the shopfloor and the trending analysis!
29 Agenda Factors influencing the cleaning and disinfection performance Recurring microbial contamination observed on the field case studies Good practices for microbial contamination control Conclusion
30 Early collaboration between vendors and end-user will change the trend! : # : #5050 Center name: Drugs Actual Total # of 483's issued: 2014: # : # : # CFR Control of microbiological contamination: (a) 'Procedures designed to prevent objectionable microorganisms in drug products not required to be sterile are not [established] [written] [followed]. Specifically, (b) 'Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include [adequate] validation of the sterilization process. Specifically, CFR (a) 21 CFR (b) 21 CFR (a) 21 CFR (b) 21 CFR Source: 21 CFR Equipment cleaning and maintenance: (a) 'Equipment and utensils are not [cleaned] [maintained] [sanitized] at appropriate intervals to prevent [malfunctions] [contamination] that would alter the safety, identity, strength, quality or purity of the drug product. Specifically, (b) Written procedures are not [established] [followed] for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product. Specifically, and 'Written procedures for cleaning and maintenance fail to include [assignment of responsibility] [maintenance and cleaning schedules] [description in sufficient detail of methods, equipment and materials used] [description in sufficient detail of the methods of disassembling and reassembling equipment as necessary to assure proper cleaning and maintenance] [instructions for removal or obliteration of previous batch identification] [instructions for protection of clean equipment from contamination prior to use] [parameters relevant to the operation]. Specifically, 21 CFR Equipment design, size, and location: Equipment used in the manufacture, processing, packing or holding of drug products is not [of appropriate design] [of adequate size] [suitably located] to facilitate operations for its [intended use] [cleaning and maintenance]. Specifically,
31 Thank You For your listening El Azab Walid Technical Service Manager STERIS
32 References Parenteral Drug Associations (2014) PDA Technical Report No. 67 : Exclusion of Objectionable Microorganism from Nonsterile Pharmaceuticals, Medical devices and cosmetics. Sutton S..(2012). What is an "Objectionable Organism"?, 2012, American Pharmaceutical Review 15(6): Sutton, S and L Jimenez. (2012). A Review of Reported Recalls Involving Microbiological Control with Emphasis on FDA Considerations of Objectionable Organisms, American Pharmaceutical Review 15(1):42-57 Tim Sandle, Assessment of the suitability of the R3A agar for the subculture of microorganisms isolated from pharmaceutical water systems. (2014). European Journal of Parenteral & Pharmaceutical Sciences 2014;19(3):85-93 Tim Sandle. (2011). A Review of Cleanroom Microflora: Types, Trends, and Patterns. PDA J Pharm Sci and Tech 2011, Lopolito, P. and Rivera, E. (2013) An Audit Approach to Address Microbial Contamination in Process Equipment, Volume 1, DHI/PDA, Chapter 15, El Azab W. (2016), Investigation of Microbiological Contamination in Water Systems: A Case Study, Contamination Control in Healthcare Product Manufacturing, Volume 4, DHI/PDA, Chapter 7 Sandle T., Understanding cleanroom flora, The Official Journal of The Institute of Science & Technology Journal, (2013) Sandle T., Peer Reviewed: Cleanroom Contamination, IVT network (people-cleanrooms-understanding-and-monitoring-personnelfactor), (2014). Madsen R., Moldenhauer J., Contamination Control in HealthCare Product Manufacturing, PDA and DHI, Vol. 3, 2013, p Lucia Stecchini M., Del Torre M., Sarais I., Saro O., Messina M., Maltini E., Influence of Structural Properties and Kinetic Constraints on Bacillus cereus Growth, Applied and Environmental Microbiology, 64 (3), (1997). Whyte W., and Eaton T., Microbiological contamination models for use in risk assessment during pharmaceutical production. European Journal of Parenteral and Pharmaceutical Sciences, 9 (1), pp (2004). Whyte W., and Eaton T., Microbial risk assessment in pharmaceutical cleanrooms. European Journal of Parenteral and Pharmaceutical Sciences, 9 (1), 16-23, (2004). Polarine J., Bartnett C., Smith T., Klein D., Karanja P., Peer Reviewed: Fungicidal Activity of Globally Acceptable Quaternary Ammonium Disinfectants, Journal of Validation Technology, 2013 Note: This is not a complete listing, just a guidance to literature the speaker has found to be interesting/beneficial.
Case study Microbiological excursion during a phase I PQ of a WFI system. Walid El Azab Technical Service Manager STERIS Life Science
Case study Microbiological excursion during a phase I PQ of a WFI system Walid El Azab Technical Service Manager STERIS Life Science Agenda Agenda Case study Microbiological excursion Description of the
More informationIs it true, Annex 1 revision will have no impact on resources or cost? Walid El Azab Technical Service Manager STERIS
Is it true, Annex 1 revision will have no impact on resources or cost? Walid El Azab Technical Service Manager STERIS Agenda Annex 1 revision why? Impact of the change on the field Conclusion The Revision
More informationResidue removal in Cleanroom Environments
Residue removal in Cleanroom Environments PDA Midwest Indianapolis Event 06 Oct 2016 Contamination Control Solutions 1/ BIO Beth Kroeger Technical Service Manager STERIS Life Sciences 4 years 24 years
More informationDisinfection Qualification Testing
Disinfection Qualification Testing Considerations for Aseptic & Cleanroom Manufacturing Environments White Paper Considerations for Aseptic and Cleanroom Manufacturing Environments Obtaining the highest
More informationCurrent Industry Trends -Including Cleaning and Disinfection trends, Disinfectant Validation Trends, and Current Warning Letter Activity.
Current Industry Trends -Including Cleaning and Disinfection trends, Disinfectant Validation Trends, and Current Warning Letter Activity. Jim Polarine Jr. MA. Technical Service Manager Steris Corp. Copyright
More informationHow to Handle Excursions in Environmental Monitoring (EM) and Personnel Monitoring (PM) in an Aseptic Processing Plant
How to Handle Excursions in Environmental Monitoring (EM) and Personnel Monitoring (PM) in an Aseptic Processing Plant Randy Hutt, Ph.D. Associate Director Sterility Assurance and Microbiology Luitpold
More informationMicrobiological Cleaning Method Validation
Microbiological Cleaning Method Validation The purpose of cleaning procedures should never be to reduce bioburden to an acceptable level! Fergus O Connell QA Manager Eurofins ams Laboratories www.eurofins.com
More informationDISINFECTION QUALIFI CATION TESTING CONSIDERATIONS FOR THE ASEPTIC AND CLEANROOM MANUFACTURING ENVIRONMENT
DISINFECTION QUALIFI CATION TESTING CONSIDERATIONS FOR THE ASEPTIC AND CLEANROOM MANUFACTURING ENVIRONMENT by Dave Rottjakob, M.T. (ASCP) December, 2013 INTRODUCTION Obtaining the highest confidence that
More informationThe Life Cycle Approach to Cleaning Validation
The Life Cycle Approach to Cleaning Validation Presented by: Elizabeth Rivera Technical Services Manager August 2015 Orlando, FL OMICS Conference 1/ Agenda Background Process Design Process Qualification
More informationPreparing Your Aseptic Processing Facility for an FDA Inspection. Valerie Welter, Director Quality Bayer HealthCare March 10, 2014
Preparing Your Aseptic Processing Facility for an FDA Inspection Valerie Welter, Director Quality Bayer HealthCare March 10, 2014 Agenda Regulatory Requirements Establishing your Approach Aseptic Controls
More informationSubpart B Organization and Personnel, 21 CFR Responsibilities of the quality control unit.
FDA inspections continue to focus on CGMP violations related to basic GMP controls. A survey of Warning Letters issued in 2013 on CMC (Chemistry / Manufacturing / Controls) violations reveals an emphasis
More informationManaging Your Environmental Isolates
Managing Your Environmental Isolates The Controversy Good practice includes the periodic challenge of prepared media with low levels of organisms. This includes USP indicator organisms as well as normal
More informationBFS IOA BFS Training 2018 Kunming Qualification and Validation of a BFS-Installation including CIP/SIP
Qualification and Validation of a BFS-Installation including CIP/SIP Presented by Christoph Bohn and Stefan Kiesel Director Rommelag Pharma Service Senior Manager Rommelag Pharma Service Coyright BFS IOA
More informationA Case Study for an Improved Approach to Cleanroom Disinfection, Minimizing the Impact and Reducing Downtime
A Case Study for an Improved Approach to Cleanroom Disinfection, Minimizing the Impact and Reducing Downtime James Tucker Global Scientific Affairs Manager Ecolab Life Science A Case Study for an Improved
More informationLUNCH AND LEARN. September 11, CE Activity Information & Accreditation
LUNCH AND LEARN Environmental Monitoring and Contamination Control September 11, 2015 Featured Speaker: Scott Sutton, Ph.D. The Microbiology Network N. Chili, New York 1 CE Activity Information & Accreditation
More information3/5/2013. Agenda. Disinfectant regulations. Case History by Mary Ellen Clark Validation Scientist MedImmune
Webinar presented March 06, 2013 Paul Lopolito Technical Services Manager STERIS Corporation paul_lopolito@steris.com Case History by Mary Ellen Clark Validation Scientist MedImmune Agenda Designing critical
More informationBioburden Contamination Control: A Holistic Overview
Bioburden Contamination Control: A Holistic Overview Scott Sutton, PhD Microbiology Network, Inc. Scott Sutton, PhD is the Principal of Microbiology Network, Inc (http:// microbiologynetwork.com/) a company
More informationAn Audit Approach to Address Microbial Contamination in Process Equipment
An Audit Approach to Address Microbial Contamination in Process Equipment Presented By Paul Lopolito, Technical Services Manager and Elizabeth Rivera, Technical Services Specialist STERIS Corporation Agenda
More informationThe Parenteral Drug Association
C O N F E R E N C E R E P O R T Equipment Cleaning Microbial Control Issues By Destin A. LeBlanc, M.A. Cleaning Validation Technologies Validation: The Parenteral Drug Association (PDA) spring conference
More informationOverview of Regulatory Requirements for API and Formulations
Overview of Regulatory Requirements for API and Formulations Sangeeta Sardesai 4-Dec-2010 Definition - Regulatory Requirement The restrictions, licenses, and laws applicable to a product or business, imposed
More informationPDA: A Global. Association. Contamination Control: Particles, Bio-contamination, Aseptic manufacturing. PDA Parenteral 2014 Munich Conference
PDA Parenteral 2014 Munich Conference PDA: A Global Contamination Control: Particles, Bio-contamination, Bioburden Association and Endotoxins in Aseptic manufacturing. James Drinkwater F Ziel Head of Aseptic
More informationCurriculum Vitae. SENIOR VICE PRESIDENT JAMES P. KULLA Mobile Phone:
Curriculum Vitae SENIOR VICE PRESIDENT JAMES P. KULLA Mobile Phone: 240.413.3350 Summary of Qualifications Jim has been active in the medical products industry since 1967. Jim founded a company in 1980
More informationPDA: A Global Association
Achieving Meticulous Aseptic Standards & Control in a Filling Isolator PDA: A Global Association Lessons for Design Aidan Harrington PhD Senior Consultant DPS Engineering, Cork Ireland Preface Agalloco,
More informationRobert Westney, M.S., RAC, CMQ/OE Director of Quality and Operations Cryologics, Inc. March 7, 2017
Robert Westney, M.S., RAC, CMQ/OE Director of Quality and Operations Cryologics, Inc. March 7, 2017 1 About the Presenter Bob Westney, M.S. QA/RA, RAC, CMQ/OE 30 years of industry experience QC Microbiology,
More informationGetting it Right Microbial Quality Risk Management
Programme Linda Musker Quality Control North West Mark Oldcorne All Wales Pharmaceutical Quality Assurance Getting it Right Microbial Quality Risk Management Strategic Background (MAO) The Problem (LM)
More informationRegulatory Aspects of Cleaning and Cleaning Validation. Larry Greenstein Quality Operations, Quality Unit, Bio-Technology General, Ltd.
Regulatory Aspects of Cleaning and Cleaning Validation Larry Greenstein Quality Operations, Quality Unit, Bio-Technology General, Ltd. 28 June 2017 Why clean? Pharmaceutical production equipment is cleaned
More informationA risk based approach to managing environmental excursions
A risk based approach to managing environmental excursions RACI: Monitoring & protecting your GMP facility s Environment 20 th April Ngoc Anh-Thu Phan www.eurofins.com Content Introduction Risk Assessment
More informationBest Practices For Cleaning Validation in the Aseptic Environment SUMMARY OF OUTLINE
Best Practices For Cleaning Validation in the Aseptic Environment Vivienne Yankah, PhD, CQE sanofi pasteur Ltd. Toronto, Canada SUMMARY OF OUTLINE Review Regulatory Standards for CV Designing and Developing
More informationCleaning and Sanitation
Cleaning and Sanitation Training Outcome of the Module: Cleaning and sanitation programs are an important part of GMP, as they protect products from environmental contamination and cross-contamination
More informationSchool of Pharmacy & Pharmaceutical Sciences QP Forum Thursday 16th April McGee Pharma International
School of Pharmacy & Pharmaceutical Sciences QP Forum Thursday 16th April 1 Parallel Session - Sterile Facilitator Ms Ann McGee 2 Query Topics Contamination Control Strategy Problems virtually managing
More informationOverview of Inspection Issues with Legacy Products
Overview of Inspection Issues with Legacy Products Presented by Simone E. Pitts Consumer Safety Officer, USFDA Team Biologics simone.pitts@fda.hhs.gov Objective To provide some examples of recent inspectional
More informationSterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM
Sterilizing and Bioburden Filter Risk Assessment in Vaccine Processes as part of QRM DCVMN Workshop, Hyderabad, 4-8 April 2016 G. Somasundaram Associate Director - Technology Management Overview Key Regulatory
More informationContamination Control in Healthcare Product Manufacturing Volume 3 Russell E. Madsen and Jeanne Moldenhauer Editors PDA Bethesda, MD, USA DHI Publishing, LLC River Grove, IL, USA 10 987654321 ISBN: 1-933722-81-9
More informationEU Guidance / Q&A. Greg McGurk, GMP Manager (acting) GMP Conference. 7 February 2017 Dublin
EU Guidance / Q&A Greg McGurk, GMP Manager (acting) GMP Conference 7 February 2017 Dublin TPN Manufacture Q&A TPN Guidance Proposed at IWG that working group be formed to draft guidance Several adverse
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Seite 1 von 10 Inspections, Compliance, Enforcement, and Criminal Investigations Laboratoire Atlas Inc. 6/25/09 hhsbluebird Department of Health and Human Services Public Health Service Food and Drug Administration
More informationHot Topics in Drug Product Process Validation: A Reviewer s Perspective
Hot Topics in Drug Product Process Validation: A Reviewer s Perspective Colleen Thomas, Ph.D. Quality Assessment Lead (Acting) FDA/CDER/OPQ/OPF Division of Microbiology Assessment CASSS CMC Strategy Forum
More informationContents. Contents (13) 1 Production (23)
1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing
More informationComplaints Investigations Root Cause Analysis
Complaints Investigations Root Cause Analysis Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018 Information presented in this presentation does
More informationGuidance for Industry
Guidance for Industry for the Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products Center for Drug Evaluation and Research (CDER) Center
More informationFDA s Guidance for Industry
Sterile Drug Products Produced by Aseptic Processing - CGMPs Midwest FDC Conference November 4 2005 Susan Bruederle, Investigator FDA / ORA / Central Region Chicago District / Hinsdale IL FDA s Guidance
More informationCompounding Pharmacies and Water
Compounding Pharmacies and Water Scott Sutton, PhD scott.sutton@microbiol.org August 21, 2014 46 Disclaimer I am an independent consultant. I have been involved with USP for many years. I do not represent
More informationWebinar Expert Module 3: GMP Inspections Dupont
Webinar Expert Module 3: GMP Inspections Dupont 26 January & 9 February 2018 GOP-Innovations your Partner for Practical Training and e-learning Milenko Pavičić Pharmaceutical microbiologist, trainer, coach
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Seite 1 von 10 Inspections, Compliance, Enforcement, and Criminal Investigations Dabur Oncology PLC hhsbluebird Department of Health and Human Services Warning Letter Public Health Service Food and Drug
More informationDisinfectant Qualification A Multifaceted Study
Disinfectant Qualification A Multifaceted Study In this article, Ziva Abraham, Microrite, Inc., gives us a brief overview of the disinfectant qualification study process. An effective cleaning and disinfection
More informationCleaning Procedures. These guidelines are intended for Bulk Pharmaceutical Chemicals but almost every word applies to Drug Products
CLEANING DEVELOPMENT Cleaning Procedures as the FDA See It These guidelines are intended for Bulk Pharmaceutical Chemicals but almost every word applies to Drug Products BPC CLEANING (& Drug Products)
More informationSupplementary Training Modules on Good Manufacturing Practice. Validation. WHO Technical Report Series, No. 937, Annex 4.
Supplementary Training Modules on Good Manufacturing Practice Validation WHO Technical Report Series, No. 937, 2006. Annex 4. Validation Slide 1 of 48 August 2006 Validation! Part 1. General overview on
More informationFormulated Chemistries for Critical Environments
STERIS CORPORATION Formulated Chemistries for Critical Environments Superior Cleaning Products Backed by Proven Expertise Unique in critical environments......................... AND/OR REGULATORY CLAIMS
More informationAt Your ServIce. Microbiology Services. The life science business of Merck operates as MilliporeSigma in the U.S. and Canada.
At Your ServIce Microbiology Services The life science business of Merck operates as MilliporeSigma in the U.S. and Canada. Microbiology Services Optimize your QC lab workflow and ensure regulatory compliance
More informationUSP <1116> and Contamination
USP and Contamination Recovery Rates Scott Sutton ABSTRACT United States Pharmacopeia (USP) "Microbiological Control and Monitoring of Aseptic Processing Environments" approaches analysis
More informationCONTENTS About the Authors xiii 1 ENVIRONMENTAL MONITORING 1 Jeanne Moldenhauer Overview 1 Components of an Environmental Control System 2 Facility Design and Maintenance 3 Documentation Systems and Procedural
More informationSystems-Based Inspections for Cleaning Validation
Systems-Based Inspections for Cleaning Validation FDA DG 230 July 27, 2015 Rockville, MD Destin A. LeBlanc Cleaning Validation Technologies www.cleaningvalidation.com 1 Objectives Describe and/or identify:
More informationMicrobiology Research Associates
2017 Microbiology Research Associates List of Services www.mra-bact.com 33 Nagog Park Acton, MA 01720 978.263.2624 Page 1 of 11 Microbiology Tests Pharma/Biotech/Medical Devices Time From Sample Receipt
More informationThis compilation of the complex
Manufacturing in a Global Marketplace Reference Matrices on Regulations for Classified (Environmentally Controlled) Areas Betty Seawell, William Miele, and Jean Huxsoll The complex world of international
More informationPROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D.
Basic GMP Requirement PROCESS VALIDATION ROCHAPON WACHAROTAYANKUN, PH.D. Topic Process validation What and Why? Principle of process validation Manufacturing process validation Aseptic process validation
More informationBiological contamination events in isolators: What lessons can be learned?
WHITE PAPER SCIENCE DRIVEN BIO-DECONTAMINATION LS001-MKT-008 Rev 1US Biological contamination events in isolators: What lessons can be learned? James Drinkwater, Bioquell UK Process & Compliance Director.
More informationGMP Regulations for Pharmaceutical Industry
CONTENTS Foreword... (v) Preface... (vii) CHAPTER 1 GMP Regulations for Pharmaceutical Industry 1.1 Basic Requirements of GMP... 1 1.2 Organization Pillars in cgmp... 2 a. Management Responsibilities...
More informationManaging Your Environmental Isolates
Managing Your Environmental Isolates Good Testing Practices Good practice includes the periodic challenge of media with low levels of organisms. This includes USP indicator organisms as well as normal
More informationTesto Expert Knowledge. The GxP Dictionary 1st edition. Definitions relating to GxP and Quality Assurance
Testo Expert Knowledge The GxP Dictionary 1st edition Definitions relating to GxP and Quality Assurance Note: Some of the information contained in this GxP Dictionary does not apply equally to all countries.
More informationEmcure Pharmaceuticals Limited 3/3/16
1 of 7 05/06/2016 8:22 AM U.S. Food and Drug Administration Protecting and Promoting Your Health Emcure Pharmaceuticals Limited 3/3/16 Department of Health and Human Services Public Health Service Food
More informationSITE MASTER FILE For MHRA
ABC CO., LTD. For MHRA Prepared by Date Approved by Date Verified by Date Document No.: SMF, Version No: 01, Effective Date: 09/05/06 Document No.: SMF Version No.: 01 Effective Date: 09/05/06 Page 2 of
More informationToday s Topics. General Quality Control Best Practices. Practices Antimicrobial Effectiveness Testing(AET) Best Practices Environmental Isolates
Laboratory Best Practices in QC Microbiology Today s Topics General Quality Control Best Practices Growth Promotion Testing (GPT) Best Practices Antimicrobial Effectiveness Testing(AET) Best Practices
More informationOverview of Inspection Issues with Legacy Products. Barbara Breithaupt Consumer Safety Officer
Overview of Inspection Issues with Legacy Products Barbara Breithaupt Consumer Safety Officer 1 Overview of the presentation The role of the Quality Unit will be discussed in the context of the inspection
More informationGMP GUIDELINES. GMP Guides from Industry Organisations. FDA cgmp WHO GMP. cgmp Guide Drugs 21 CFR 210 GAMP. ISPE Technical Guides
FDA cgmp cgmp Guide Drugs 21 CFR 210 cgmp Guide Drugs 21 CFR 211 cgmp Guide Medical Device 21 CFR 808, 812, 820 cgmp Guide Biologics 21 CFR 600, 606, 610 Guideline List Human Drugs Guideline List Biologics
More informationBest Practice in Environmental Monitoring
Best Practice in Environmental Monitoring Annette Grundy July 12 2016 1 Acknowledgement Dr Ed Tidswell previous roles at Baxter Senior Director R&D and Quality Director USP expert committee member Ed was
More informationTechnical Report No. 70 Fundamentals of Cleaning and Disinfection Programs for Aseptic Manufacturing Facilities
Technical Report No. 70 Fundamentals of Cleaning and Disinfection Programs for Aseptic Manufacturing Facilities PDA Fundamentals of Cleaning and Disinfection Programs for Aseptic Manufacturing Facilities
More informationMicrobiological Consideration for Non-Sterile Pharmaceutical
May 1-3, 2012 Javits Center New York, NY Microbiological Consideration for Non-Sterile Pharmaceutical Dr. Leonard W. Mestrandrea Principal Consultant MESTRANDREA CONSULTING LLC Title Date Microbial Control
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.
More informationJournal of Atoms and Molecules
Review article Journal of Atoms and Molecules An International Online Journal ISSN 2277 1247 CLEANING VALIDATION IN PHARMACEUTICAL INDUSTRIES Abhishek Raj Senior R&D Officer, Quest Pharmaceuticals Pvt.
More informationCalibration in the Laboratory
IVT Validation Week 2015 Calibration in the Laboratory 2015 The Lanese Group, Inc. Jerry Lanese Ph.D. The Lanese Group, Inc. 1 Outline Overview of laboratory data integrity Elements of the Laboratory Instrument
More informationMicrobiology Testing: USP requirements for Sterile and Nonsterile Preparations Webinar Q&A
USP Antimicrobial Effectiveness Testing Microbiology Testing: Webinar Q&A 1. If a base ingredient is designed for the purpose of compounding a specific type of preparation does this forgo the necessity
More informationfor IND and RDRC Regulated PET Compounding
Overview of USP Chapter for IND and RDRC Regulated PET Compounding Distributed Manufacturing of PET Radiopharmaceuticals for Multi-Center Clinical Trials SNM, Annual Meeting Toronto, Ontario, Canada
More informationGMP Manual. Contents. Contents (1) 1 Pharmaceutical Quality System (PQS) 2 Personnel
GMP Manual GMP Manual 1 Pharmaceutical Quality System (PQS) 1.A Preface 1.B The road to a Pharmaceutical Quality System 1.C Introduction to the PQS 1.C.1 General requirements 1.C (1) 1.C.2 Documentation
More informationCompounding Pharmacies and the USP <71> Sterility Tests
Compounding Pharmacies and the USP Sterility Tests Scott Sutton, Ph.D. scott.sutton@microbiol.org 49 41 Disclaimer I am making this presentation as an independent agent I am not making this presentation
More informationOn-Site GMP Training GMP COMPLIANCE TECHNICAL
PharmaNet On-Site GMP Training GMP COMPLIANCE TECHNICAL 284 E Lake Mead Pkwy Suite C-278 Henderson, NV 89015 Phone: 702-558-0094 Fax: 702-558-0079 www.gmpseminars.com Key to Level of Program Level A: Program
More informationEquipment Design Consideration for Cleaning & Cleaning Validation
Equipment Design Consideration for Cleaning & Cleaning Validation Gamal Amer, Ph. D. Principal Premier Compliance Services, Inc. All rights reserved. Do not copy without permission. 1 Cleaning and Cleaning
More informationLibrary Guide: Active Pharmaceutical
Library Guide: Active Pharmaceutical Ingredients (API) Table of Contents Overview...3 Sample Curriculum...5 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)...7 A Tour of the
More informationOutsourcing - managing risks and opportunities over which you now have less control
Outsourcing - managing risks and opportunities over which you now have less control Kevin O Donnell, PhD PDA Meeting, Dublin 22 nd November 2018 Slide 2 Typical Examples The key GMP Requirements & Guidance
More informationMICROBIOLOGICAL CULTURE MEDIA
MICROBIOLOGICAL CULTURE MEDIA A COMPLETE GUIDE FOR PHARMACEUTICAL AND HEALTHCARE MANUFACTURERS Tim Sandle Microbiological Culture Media: A Complete Guide for Pharmaceutical and Healthcare Manufacturers
More informationAseptic Process Validation
Aseptic Process Validation IMB GMP Information Seminar 27 th September 2012 Gerard Sheridan, Inspector Date Insert on Master Slide Slide 1 Overview Guidance Best Practices Common Deficiencies Slide 2 Aseptic
More informationEnvironmental Monitoring of Aseptic Processing Areas - 1
Environmental Monitoring of Aseptic Processing Areas - 1 A war against an invisible enemy DCVMN - Víctor Maqueda - May 30, 31, June 1 2016 1 Training Course Agenda Overview of Environmental Monitoring
More informationWebinar. The New EU-GMP Annex 1 draft Dupont. GOP-Innovations your Partner for Practical Training and e-learning. 8 June 2018
Webinar The New EU-GMP Annex 1 draft Dupont 8 June 2018 GOP-Innovations your Partner for Practical Training and e-learning Milenko Pavičić Pharmaceutical microbiologist, consultant, trainer, coach 10 years
More informationIndustry Case Study: A Microbial Investigation of Contamination by Burkholderia multivorans. Jim Klein and Geert Verdonk Merck & Co., Inc.
Industry Case Study: A Microbial Investigation of Contamination by Burkholderia multivorans Jim Klein and Geert Verdonk Merck & Co., Inc. Messages The role of microbiological analysis The role of subject
More informationJulie Roberts. Audit hot Topics and Regulatory Requirements
Julie Roberts Audit hot Topics and Regulatory Requirements Overview Hot Topics Examples in warning letters Tips to detecting data integrity Recent changes in regulatory requirements Hot Topics Microbial
More informationT H E P R O P O S A L F O R T H E Y E A R
Training T H E P R O P O S A L F O R T H E Y E A R 2 0 1 9 Our GMP courses combine a convenient format with an effective, interactive learning experience. To maximize and customize your professional development.
More informationCOMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION
COMPLIANCE WITH EU ANNEX 15: VALIDATION AND QUALIFICATION Paul L. Pluta, PhD Journal of Validation Technology Journal of GXP Compliance University of Illinois at Chicago (UIC) College of Pharmacy, Chicago,
More informationWARNING LETTER AUG 3, 2016
Ropack, Inc. 8/3/16 Department of Health and Human Services Public Health Service Food and Drug Administration 10903 New Hampshire Avenue White Oak Building 66 Silver Spring, MD 20993 WARNING LETTER AUG
More informationIN THIS SECTION MICROBIOLOGY TESTING EXPERT SOLUTIONS FOR PRODUCT DEVELOPMENT. Bacterial Endotoxin (LAL) Testing
EXPERT SOLUTIONS FOR PRODUCT DEVELOPMENT IN THIS SECTION MICROBIOLOGY TESTING Microbial assays involve a variety of tests, from the determination of the numbers and types of organisms naturally present
More informationTrinity College Dublin QP Forum 2017 Tuesday 25 th April
Trinity College Dublin QP Forum 2017 Tuesday 25 th April HPRA QUESTIONS & ANSWERS 1. What is the approach being taken for audit of contamination control strategies as per chapters 3 & 5? What is the current
More informationGuidance. Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE
Guidance Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and
More informationQuality by Design in Critical Filtration Operations
Quality by Design in Critical Filtration Operations Michael Payne Senior Biosafety Technical Consultant Yanglin Mok Technical Manager Objectives Define quality by design (QbD) and Quality Risk Management
More informationSIX ESSENTIAL WORKFLOW STEPS FOR PAPERLESS, AUTOMATED, END-TO-END ENVIRONMENTAL MONITORING
WHITEPAPER SIX ESSENTIAL WORKFLOW STEPS FOR PAPERLESS, AUTOMATED, END-TO-END ENVIRONMENTAL MONITORING The consequences of microbiological contamination of drug products run the gamut from FDA warning letters
More informationOverview and Introduction Annex 1 Revision
Overview and Introduction Annex 1 Revision Paul Moody, Inspector Pharmig Current Hot Topics in Pharmaceutical Microbiology, Dublin May 30 th, 2018 Scope History Process of Revision Rationale for Revision
More informationHVAC and Risk Management RACI Meeting 7 th December Agenda. Design. Project Management. Context. Qualification. Construction
HVAC and Risk Management RACI Meeting 7 th December 2011 Dr Stephen Firmer Asia Pacific Consultants Pty Ltd Agenda Context Project Management Design Construction Qualification Routine Control /Potential
More informationTECHNICAL LEAFLET. MEDI-MEDIA-FILL KIT SUPPLY PACKAGE (Code: MR-25/S)
TECHNICAL LEAFLET MEDI-MEDIA-FILL KIT SUPPLY PACKAGE (Code: MR-25/S) TEST AGAR PLATES FOR PERSONNEL AND ENVIRONMENTAL MICROBIOLOGICAL MONITORING COMPONENTS: Test Agar Plates Data Log Sheet Technical Leaflet
More informationChange Control Overview
Change Control Overview Kelly Thomas Atlantic Technical and Validation Services Copyright 2014 by Atlantic Technical and Validation Services, LLC. 1 Session Outline Discuss Regulations Governing Change
More informationIncremental GMPs. Presented by: Karen S. Ginsbury For: IFF October 31, Nov 02, PCI Pharmaceutical Consulting Israel Ltd.
Incremental GMPs Presented by: Karen S. Ginsbury For: IFF October 31, Nov 02, 2017 1/55 Sound Science Good Development Practice Traceability R&D Tox I II III IV What You Need Here Can t be generated here
More informationPorton Biopharma Limited 1/17/17
Porton Biopharma Limited 1/17/17 10903 New Hampshire Avenue Silver Spring, MD 20993 Via UPS Warning Letter 320 17 19 Return Receipt Requested January 19, 2017 Dr. Roger J. Hinton Managing Director Porton
More informationLABORATORY COMPLIANCE
1 LABORATORY COMPLIANCE Jeanne Moldenhauer Vectech Pharmaceutical Consultants, Inc. Farmington Hills, MI INTRODUCTION Implementation of the Systems-Based Inspection Guideline for drug manufacturers in
More informationHow is Sterilization Validation Performed by the Medical Device Manufacturer?
How is Sterilization Validation Performed by the Medical Device Manufacturer? Rod Parker, Ph.D. Sr. Principal Scientist Stryker Instruments Division May 9, 2016 DISCLOSURE I am an employee of Stryker Corporation.
More informationRecent USP Updates May, 2013
Recent USP Updates May, 2013 Don Singer GSK Bioburden Control of Non-sterile Drug Substances and Products The chapter emphasizes control as a risk mitigation strategy The chapter recommends a risk-based
More information